G
Glinx
The leading animal health technology company in China
About Glinx
Established in 2018, Shanghai Glinx Biotechnology Co., Ltd. is a specialized firm operating in the veterinary in-vitro diagnostics (IVD) market. The company is headquartered in Shanghai with a dedicated research and development center located in Xi'an. Glinx was founded by a team with extensive experience in medical diagnostics, animal health, and data analysis, with most founding members having backgrounds in world-renowned companies.
Read full description
Glinx addresses the needs of veterinarians and pet owners by providing advanced diagnostic solutions for both pets and livestock. The company serves over 15,000 hospitals and clinics across more than 30 countries and supports approximately 43,000 veterinarians in predicting, preventing, and treating animal diseases. Its business model centers on the development and sale of diagnostic hardware and reagents. The company has developed over 100 reagents for animal health.
The company's product portfolio includes a suite of diagnostic instruments designed for in-clinic use. Key products include the FiDX, a fluorescent immunoassay analyzer that provides quantitative results for 15 different parameters in minutes, such as Feline NT-proBNP and Canine Pancreatic Lipase. Other instruments are the InCycle Point-of-Care Molecular Analyzer, the InCoag Fully-automated Coagulation Analyzer, and automatic biochemical and hematology analyzers. These devices are designed to be efficient, requiring small sample sizes and delivering rapid, precise results. Complementing its hardware, Glinx has developed the Glinx INHUB, an intelligent animal health management system that utilizes the internet of things and artificial intelligence for laboratory management.
At a glance
- Status
- Closed
- Founded
- 2017
- Headquarters
- China
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Marketplace & ecommerce
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Glinx.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2021 | $30M | $120M | Sinovation Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Glinx is 50 monthly website visits, down 80.8% over the last three months. Glinx's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Glinx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Glinx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.